428 related articles for article (PubMed ID: 7513108)
1. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases.
Partin AW; Pearson JD; Landis PK; Carter HB; Pound CR; Clemens JQ; Epstein JI; Walsh PC
Urology; 1994 May; 43(5):649-59. PubMed ID: 7513108
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control.
Pound CR; Partin AW; Epstein JI; Walsh PC
Urol Clin North Am; 1997 May; 24(2):395-406. PubMed ID: 9126237
[TBL] [Abstract][Full Text] [Related]
3. Digital rectal examination and imaging studies are unnecessary in men with undetectable prostate specific antigen following radical prostatectomy.
Pound CR; Christens-Barry OW; Gurganus RT; Partin AW; Walsh PC
J Urol; 1999 Oct; 162(4):1337-40. PubMed ID: 10492192
[TBL] [Abstract][Full Text] [Related]
4. Natural history of progression after PSA elevation following radical prostatectomy.
Pound CR; Partin AW; Eisenberger MA; Chan DW; Pearson JD; Walsh PC
JAMA; 1999 May; 281(17):1591-7. PubMed ID: 10235151
[TBL] [Abstract][Full Text] [Related]
5. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
6. Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years.
Partin AW; Pound CR; Clemens JQ; Epstein JI; Walsh PC
Urol Clin North Am; 1993 Nov; 20(4):713-25. PubMed ID: 7505980
[TBL] [Abstract][Full Text] [Related]
7. How to explore the patient with a rising PSA after radical prostatectomy: defining local versus systemic failure.
Jhaveri FM; Klein EA
Semin Urol Oncol; 1999 Aug; 17(3):130-4. PubMed ID: 10462315
[TBL] [Abstract][Full Text] [Related]
8. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
Kupelian PA; Katcher J; Levin HS; Klein EA
Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
[TBL] [Abstract][Full Text] [Related]
9. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
[TBL] [Abstract][Full Text] [Related]
10. Prostate specific antigen only progression of prostate cancer.
Moul JW
J Urol; 2000 Jun; 163(6):1632-42. PubMed ID: 10799151
[TBL] [Abstract][Full Text] [Related]
11. Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy.
Cadeddu JA; Partin AW; DeWeese TL; Walsh PC
J Urol; 1998 Jan; 159(1):173-7; discussion 177-8. PubMed ID: 9400465
[TBL] [Abstract][Full Text] [Related]
12. Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy.
O'Brien MF; Cronin AM; Fearn PA; Smith B; Stasi J; Guillonneau B; Scardino PT; Eastham JA; Vickers AJ; Lilja H
J Clin Oncol; 2009 Aug; 27(22):3591-7. PubMed ID: 19506163
[TBL] [Abstract][Full Text] [Related]
13. Medically and economically appropriate follow-up schedule for prostate cancer patients after radical prostatectomy.
Niwakawa M; Tobisu K; Fujimoto H; Matsuoka N; Kakizoe T
Int J Urol; 2002 Mar; 9(3):134-40. PubMed ID: 12010322
[TBL] [Abstract][Full Text] [Related]
14. Digital rectal examination is no longer necessary in the routine follow-up of men with undetectable prostate specific antigen after radical prostatectomy: the implications for follow-up.
Chaplin BJ; Wildhagen MF; Schroder FH; Kirkels WJ; Bangma CH
Eur Urol; 2005 Dec; 48(6):906-10. PubMed ID: 16126322
[TBL] [Abstract][Full Text] [Related]
15. Oncologic outcomes at 10 years following robotic radical prostatectomy.
Diaz M; Peabody JO; Kapoor V; Sammon J; Rogers CG; Stricker H; Lane Z; Gupta N; Bhandari M; Menon M
Eur Urol; 2015 Jun; 67(6):1168-1176. PubMed ID: 24996687
[TBL] [Abstract][Full Text] [Related]
16. Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen.
Patel A; Dorey F; Franklin J; deKernion JB
J Urol; 1997 Oct; 158(4):1441-5. PubMed ID: 9302139
[TBL] [Abstract][Full Text] [Related]
17. Predicting disease recurrence in intermediate and high-risk patients undergoing radical prostatectomy using percent positive biopsies: results from CaPSURE.
Grossfeld GD; Latini DM; Lubeck DP; Broering JM; Li YP; Mehta SS; Carroll PR
Urology; 2002 Apr; 59(4):560-5. PubMed ID: 11927314
[TBL] [Abstract][Full Text] [Related]
18. Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics.
Graefen M; Noldus J; Pichlmeier U; Haese A; Hammerer P; Fernandez S; Conrad S; Henke R; Huland E; Huland H
Eur Urol; 1999; 36(1):21-30. PubMed ID: 10364651
[TBL] [Abstract][Full Text] [Related]
19. Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy.
Raj GV; Partin AW; Polascik TJ
Cancer; 2002 Feb; 94(4):987-96. PubMed ID: 11920467
[TBL] [Abstract][Full Text] [Related]
20. Relapse after radical prostatectomy correlates with preoperative PSA velocity and tumor volume: results from a screening population.
Berger AP; Deibl M; Strasak A; Bektic J; Pelzer A; Steiner H; Spranger R; Fritsche G; Bartsch G; Horninger W
Urology; 2006 Nov; 68(5):1067-71. PubMed ID: 17095070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
